Al-Hazmi, M, Ayoola, EA, Abdurahman, M et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis. 2003; 36: 245–52.10.1086/345671CrossRefGoogle ScholarPubMed

Anywaine, Z, Lule, SA, Hansen, C et al. Clinical manifestations of Rift Valley fever in humans: systematic review and meta-analysis. PLoS Negl Trop Dis. 2022; 16(3): e0010233. doi: 10.1371/journal.pntd.0010233.CrossRefGoogle ScholarPubMed

Baudin, M, Jumaa, AM, Jomma, HJE et al. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob Health. 2016; 4(11): e864–e871. doi: 10.1016/S2214-109X(16)30176-0.CrossRefGoogle ScholarPubMed

Choi, JH, Croyle, MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs 2013; 27(6):565–83.CrossRefGoogle ScholarPubMed

Eberhardt, KA, Mischlinger, J, Jordan, S et al. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int J Infect Dis. 2019; 87: 15–20. doi: 10.1016/j.ijid.2019.07.015.CrossRefGoogle ScholarPubMed

Garrison, AR, Alkhovsky SV, Avšič-Županc T et al. ICTV virus taxonomy profile: Nairoviridae. J Gen Virol. 2020; 101(8): 798–9. doi: 10.1099/jgv.0.001485.CrossRefGoogle ScholarPubMed

Grard, G, Fair, JN, Lee, D et al. A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog. 2012; 8(9): e1002924. doi: 10.1371/journal.ppat.1002924.CrossRefGoogle ScholarPubMed

Hunt, L, Gupta-Wright, A, Simms, V et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015; 15(11): 1292–9.10.1016/S1473-3099(15)00144-9CrossRefGoogle ScholarPubMed

Ikegami, T, Makino, S. The pathogenesis of Rift Valley fever. Viruses 2011; 3(5): 493–519. doi: 10.3390/v3050493.CrossRefGoogle ScholarPubMed

Jacobs M, Rodger A, Bell DJ. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016; 388(10043): 498–503.10.1016/S0140-6736(16)30386-5CrossRefGoogle Scholar

Jacob, ST, Crozier, I, Fischer, WA et al. Ebola virus disease. Nat Rev Dis Primers 2020; 6(1): 13.10.1038/s41572-020-0147-3CrossRefGoogle ScholarPubMed

Kabami, ZB, Kyobe H, et al. Ebola disease outbreak caused by the Sudan virus in Uganda, 2022: a descriptive epidemiological study. Lancet Glob Health 2022; 12(10): e1684–92.Google Scholar

Kafetzopoulou, LE, Pullan, ST, Lemey, P et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 2019; 363(6422): 74–7. doi: 10.1126/science.aau9343.CrossRefGoogle ScholarPubMed

Lado, M, Walker, N, Baker, P et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2015; 15(9): 1024–33.10.1016/S1473-3099(15)00137-1CrossRefGoogle ScholarPubMed

McCormick, JB, Webb, PA, Krebs, JW et al. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987a; 155: 437–44.10.1093/infdis/155.3.437CrossRefGoogle ScholarPubMed

McCormick, JB, King, IJ, Webb, PA et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987b; 155: 445–55.CrossRefGoogle ScholarPubMed

Olschläger, S, Lelke, M, Emmerich, P et al. Improved detection of Lassa virus by reverse transcription-PCR targeting the 5’ region of S RNA. J Clin Microbiol. 2010; 48(6): 2009 –13. doi: 10.1128/JCM.02351-09.Google Scholar

Petrova, V, Kristiansen, P, Norheim, G et al. Rift Valley fever: diagnostic challenges and investment needs for vaccine development. BMJ Glob Health 2020; 5(8): e002694. doi: 10.1136/bmjgh-2020-002694.CrossRefGoogle ScholarPubMed

Pleet, ML, DeMarino, C, Lepene, B, Aman, MJ, Kashanchi, F. The role of exosomal VP40 in Ebola virus disease. DNA Cell Biol. 2017; 36(4): 243–8.10.1089/dna.2017.3639CrossRefGoogle ScholarPubMed

van Schalkwyk, A, Romito, M. Genomic characterization of Rift Valley fever virus, South Africa, 2018. Emerg Infect Dis. 2019; 25(10): 1979–81. doi: 10.3201/eid2510.181748.CrossRefGoogle ScholarPubMed

Seufi, AM, Galal, FH. Role of Culex and Anopheles mosquito species as potential vectors of Rift Valley fever virus in Sudan outbreak, 2007. BMC Infect Dis. 2010; 10, 65. https://doi.org/10.1186/1471-2334-10-65.Google Scholar

Takah, NF, Brangel, P, Shrestha, P. et al. Sensitivity and specificity of diagnostic tests for Lassa fever: a systematic review. BMC Infect Dis. 2019; 19, 647. https://doi.org/10.1186/s12879-019-4242-6.CrossRefGoogle ScholarPubMed

Velasquez, GE, Aibana, O, Ling, EJ et al. Time from infection to disease and infectiousness for Ebola virus disease: a systematic review. Clin Infect Dis. 2015; 61(7): 1135–40.10.1093/cid/civ531CrossRefGoogle ScholarPubMed

WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health care workers, 2016; Geneva: WHO.Google Scholar

WHO. Annual review of diseases prioritized under the Research and Development Blueprint. 2018; Geneva: WHO.Google Scholar

WHO. Optimized supportive care for Ebola virus disease: clinical management standard operating procedures. 2019; Geneva: WHO.Google Scholar

Bah, EI, Lamah, MC, Fletcher, T et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015; 372(1):40–7.10.1056/NEJMoa1411249CrossRefGoogle ScholarPubMed

Bente, DA, Forrester, NL, Watts, DM et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 2013; 100(1): 159–89.10.1016/j.antiviral.2013.07.006CrossRefGoogle ScholarPubMed

Davis, C, Tipton, T, Sabir, S et al. Postexposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the United Kingdom: an operational, safety, and immunogenicity report. Clin Infect Dis. 2020; 71(11): 2872–9.Google ScholarPubMed

Filoviruses: Journal of Infectious Diseases; 196: Suppl. 2, 2007. This supplement collects a range of papers on all aspects of filovirus research, and in-depth description of the outbreak response to the Uige Marburg epidemic.Google Scholar

Gargili, A, Estrada-Peña, A, Spengler, JR et al. The role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: a review of published field and laboratory studies. Antiviral Res. 2017; 144: 93–119.CrossRefGoogle ScholarPubMed

Henao-Restrepo, AM, Camacho, A, Longini, IM et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017; 389(10068): 505–18. doi: 10.1016/S0140-6736(16)32621-6.CrossRefGoogle ScholarPubMed

Hoogstraal, H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol. 1979; 15(4): 307–417.10.1093/jmedent/15.4.307CrossRefGoogle ScholarPubMed

Journal of Infectious Diseases; 179: Suppl. 1, 1999. This is a special edition reporting all epidemiological, clinical, virological and laboratory data collected during the Ebola outbreak in Kikwit, DRC, 1995. This is available free at www.journals.uchicago.edu/JID/journal/contents/v179nS1.Html.Google Scholar

Juan-Giner, A, Kimathi, D, Grantz, KH et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet 2021; 397(10269): 119–27. doi: 10.1016/S0140-6736(20)32520-4.CrossRefGoogle ScholarPubMed

Kallas, EG, Wilder-Smith, A. Managing severe yellow fever in the intensive care: lessons learnt from Brazil. J Travel Med. 2019; 26(5): taz043. doi: 10.1093/jtm/taz043.Google ScholarPubMed

Low, JG, Ng, JHJ, Ong, EZ et al. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N Engl J Med. 2020; 383(5): 452–9. doi: 10.1056/NEJMoa2000226.Google ScholarPubMed

Messina, JP, Pigott, DM, Duda, KA et al. A global compendium of human Crimean–Congo haemorrhagic fever virus occurrence. Sci Data 2015; 2: 150016.10.1038/sdata.2015.16CrossRefGoogle ScholarPubMed

Mulangu, S, Dodd, LE, Davey, RT Jr et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019; 381(24): 2293–303. doi: 10.1056/NEJMoa1910993.CrossRefGoogle ScholarPubMed

Paweska, JT, Sewlall, NH, Ksiazek, TG et al. Outbreak control and investigation teams. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis. 2009;15(10): 1598–602. doi: 10.3201/eid1510.090211.Google Scholar

Spengler, JR, Bente, DA, Bray, M et al. Second International Conference on Crimean-Congo Hemorrhagic Fever. Antiviral Res. 2018; 150: 137–47.10.1016/j.antiviral.2017.11.019CrossRefGoogle ScholarPubMed

Temur, AI, Kuhn, JH, Pecor, DB et al. Epidemiology of Crimean-Congo hemorrhagic fever (CCHF) in Africa – underestimated for decades. Am J Trop Med Hygiene 2021; 104(6): 1978–90.10.4269/ajtmh.20-1413CrossRefGoogle ScholarPubMed

Thorson, AE, Deen, GF, Bernstein, KT et al. Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: a cohort study of frequency, duration, and risk factors. PLoS Med. 2021; 18(2): e1003273. doi: 10.1371/journal.pmed.1003273.CrossRefGoogle ScholarPubMed

WHO (1997). WHO guidelines for epidemic preparedness and response: Ebola haemorrhagic fever (EHF). WHO Document: WHO/EMC/ DIS/97.7.Google Scholar

CDC. Transmission of yellow fever virus. www.cdc.gov/yellowfever/transmission/index.html.Google Scholar

de Menezes Martins, R., Maia, M. de L. S., de Lima, S. M. B. et al. (2018). Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine, 36(28), 4112–4117. doi.org/10.1016/j.vaccine.2018.05.041.CrossRefGoogle ScholarPubMed

Garske, T., van Kerkhove, M. D., Yactayo, S. et al. (2014). Yellow fever in Africa: Estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Medicine, 11(5), e1001638. doi.org/10.1371/journal.pmed.1001638.CrossRefGoogle ScholarPubMed

Juan-Giner, A., Kimathi, D., Grantz, K. H. et al. (2021). Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet, 397(10269), 119–127. doi.org/10.1016/S0140-6736(20)32520-4.CrossRefGoogle ScholarPubMed

Mokaya, J., Kimathi, D., Lambe, T. & Warimwe, G.M. (2021). What constitutes protective immunity following yellow fever vaccination? Vaccines, 9(6), 671. doi.org/10.3390/vaccines9060671.CrossRefGoogle ScholarPubMed

Monath, T. P. (2001). Yellow fever: an update. Lancet Infectious Diseases, 1(1), 11–20. doi.org/10.1016/S1473-3099(01)00016-0.CrossRefGoogle ScholarPubMed

Strode, G.K., Bugher, J.C. & Kerr, J.A. (1951). In Strode, G. K. (ed.) Yellow Fever. New York: McGraw-Hill Book Co.Google Scholar

WHO (2008). Detection and investigation of serious adverse events following yellow fever vaccination. https://apps.who.int/iris/bitstream/handle/10665/70251/WHO_HSE_GAR_ERI_2010.2_eng.pdf?sequence=1.Google Scholar

WHO (2013). Weekly epidemiological record: vaccines and vaccination against yellow fever. www.who.int/wer.Google Scholar

WHO (2017). Eliminate yellow fever epidemics by 2026 (EYE). www.who.int/csr/disease/yellowfev/eye-strategy-one-pager.pdf.Google Scholar

Bruha, R., Dvorak, K., Petrtyl, J. (2012). Alcoholic liver disease. World J Hepatol. 4(3): 81–90.10.4254/wjh.v4.i3.81CrossRefGoogle ScholarPubMed

Elsharkawy, A., El-Raziky, M., El-Akel, W. et al. (2018). Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience. J Hepatol. 68: 691–698.10.1016/j.jhep.2017.11.034CrossRefGoogle ScholarPubMed

Francis, J.M., Grosskurth, H., Changalucha, J. et al. (2014). Systematic review and meta-analysis: prevalence of alcohol use among young people in eastern Africa. Trop Med Int Health 19(4): 476–488.10.1111/tmi.12267CrossRefGoogle ScholarPubMed

GBD 2017 Cirrhosis Collaborators (2020) The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 5(3): 245–266.Google Scholar

Koff, R.S. (1998). Hepatitis, A. Lancet 351(9116): 1643–1649.Google Scholar

Omotayo, O.P., Omotayo, A.O., Mwanza, M. et al. (2019). Prevalence of mycotoxins and their consequences on human health. Toxicol Res. 35(1): 1–7.10.5487/TR.2019.35.1.001CrossRefGoogle ScholarPubMed

Stockdale, A.J., Chaponda, M. Beloukas, A. et al. (2017). Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. The Lancet Global Health, 5(10): e992–e1003.10.1016/S2214-109X(17)30298-XCrossRefGoogle ScholarPubMed

Waked, I., Esmat, G., Elsharkawy, A. et al. (2020). Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med. 382(12): 1166–1174.10.1056/NEJMsr1912628CrossRefGoogle ScholarPubMed

WHO (2015). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. www.who.int/publications/i/item/9789241549059.Google Scholar

WHO (2018). Global status report on alcohol and health 2018. https://apps.who.int/iris/handle/10665/274603.Google Scholar

WHO (2021). Hepatitis E factsheet. www.who.int/news-room/fact-sheets/detail/hepatitis-e.Google Scholar

Balakrishnan, T. et al. (2011). Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PloS ONE 6(12). doi.org/10.1371/journal.pone.0029430.CrossRefGoogle ScholarPubMed

Bhatt, P. et al. (2021). Current understanding of the pathogenesis of dengue virus infection. Current Microbiology 78(1):17–32.10.1007/s00284-020-02284-wCrossRefGoogle ScholarPubMed

Carrington, L. B. & Simmons, C. P. (2014). Human to mosquito transmission of dengue viruses. Frontiers in Immunology 5:290. doi.org/10.3389/fimmu.2014.00290.CrossRefGoogle ScholarPubMed

Chen, H. R., Lai, Y. C. & Yeh, T. M. (2018). Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate. Journal of Biomedical Science 25(1):58.10.1186/s12929-018-0462-0CrossRefGoogle ScholarPubMed

Etymologia: dengue. (2006). Centers for Disease Control and Prevention (CDC), Emerging Infectious Diseases 12(6):893.Google Scholar

Fritzell, C. et al. (2018). Current challenges and implications for dengue, chikungunya and Zika seroprevalence studies worldwide: a scoping review. PLoS Neglected Tropical Diseases 12(7):e0006533.10.1371/journal.pntd.0006533CrossRefGoogle ScholarPubMed

Guzman, M. G. et al. (2010). Dengue: a continuing global threat. Nature Reviews Microbiology 8(12):S7–S16.10.1038/nrmicro2460CrossRefGoogle ScholarPubMed

Hadinegoro, S. R. S. (2012). The revised WHO dengue case classification: does the system need to be modified? Paediatrics and International Child Health 32(s1):33–38.CrossRefGoogle ScholarPubMed

Halstead, S. M. (2017). Dengue and dengue hemorrhagic fever. In Handbook of Zoonoses, 2nd ed. Section B: Viral Zoonoses, 89–99. Baco Raton: CRC Press.Google Scholar

Jaenisch, T. et al. (2014). Dengue expansion in Africa—not recognized or not happening? Emerging Infectious Diseases 20(10). doi: 10.3201/eid2010.140487.CrossRefGoogle ScholarPubMed

Kuhn, R. J. et al. (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108(5):717–725.10.1016/S0092-8674(02)00660-8CrossRefGoogle ScholarPubMed

Lee, J.-S. et al. (2019). A multi-country study of the economic burden of dengue fever based on patient-specific field surveys in Burkina Faso, Kenya, and Cambodia. PLOS Neglected Tropical Diseases 13(2). doi.org/10.1371/journal.pntd.0007164.CrossRefGoogle Scholar

Nedjadi, T. et al. (2015). Tackling dengue fever: current status and challenges. Virology Journal 12:212.10.1186/s12985-015-0444-8CrossRefGoogle ScholarPubMed

PAHO. (2020). Algorithms for the Clinical Management of Dengue Patients. www.paho.org/en/documents/algorithms-clinical-management-dengue-patients.Google Scholar

Peeling, R. W. et al. (2010). Evaluation of diagnostic tests: dengue. Nature Reviews Microbiology. 8(12):S30–S38.10.1038/nrmicro2459CrossRefGoogle ScholarPubMed

Pinheiro-Michelsen, J. R. et al. (2020). Anti-dengue vaccines: from development to clinical trials. Frontiers in Immunology 11:1252.10.3389/fimmu.2020.01252CrossRefGoogle ScholarPubMed

Rivino, L. et al. (2015). Virus-specific T lymphocytes home to the skin during natural dengue infection. Science Translational Medicine 7(278):278ra35.10.1126/scitranslmed.aaa0526CrossRefGoogle Scholar

Screaton, G. et al. (2015). New insights into the immunopathology and control of dengue virus infection. Nature Reviews Immunology 15:745–759.10.1038/nri3916CrossRefGoogle ScholarPubMed

Silva, N. M., Santos, N. C. & Martins, I. C. (2020). Dengue and zika viruses: epidemiological history, potential therapies, and promising vaccines. Tropical Medicine and Infectious Disease 5(4). doi: 10.3390/tropicalmed5040150.CrossRefGoogle ScholarPubMed

St. John, A. L. & Rathore, A. P. S. (2019). Adaptive immune responses to primary and secondary dengue virus infections. Nature Reviews Immunology. 19:218–230.10.1038/s41577-019-0123-xCrossRefGoogle ScholarPubMed

Troost, B. & Smit, J. M. (2020). Recent advances in antiviral drug development towards dengue virus. Current Opinion in Virology 43:9–21.10.1016/j.coviro.2020.07.009CrossRefGoogle ScholarPubMed

Warkentien, T. & Pavlicek, R. (2016). Dengue fever: historical perspective and the global response. Journal of Infectious Diseases and Epidemiology 2(2). doi: 10.23937/2474-3658/1510015.CrossRefGoogle Scholar

WHO. (2017). Global vector control response 2017–2030.Google Scholar

WHO. (2021). Dengue and severe dengue.Google Scholar

WHO. (2016). Laboratory testing for Zika virus infection: interim guidance.Google Scholar

Zeng, Z. et al. (2021). Global, regional, and national dengue burden from 1990 to 2017: a systematic analysis based on the global burden of disease study 2017. EClinicalMedicine 32:100712.10.1016/j.eclinm.2020.100712CrossRefGoogle ScholarPubMed

Awasthi, M., Parmar, H., Patankar, T. et al. (2001). Imaging findings in rabies encephalitis. Am J Neuroradiology, 22 (4): 677–680.Google ScholarPubMed

Begeman, L., GeurtsvanKessel, C., Finke, S. et al. (2018). Comparative pathogenesis of rabies in bats and carnivores, and implications for spillover to humans. Lancet Inf Dis, 18(4): e147–e159. doi: 10.1016/S1473-3099(17)30574-1.CrossRefGoogle ScholarPubMed

Burdon Bailey, J. L., Gamble, L., Gibson, A. D. et al. (2018). A rabies lesson improves rabies knowledge amongst primary school children in Zomba, Malawi. PLoS Negl Trop Dis, 12(3): e0006293. https://doi.org/10.1371/journal.pntd.0006293CrossRefGoogle ScholarPubMed

Howlett, W. P. (2015). Rabies. In Neurology in Africa, 141–144. Cambridge: Cambridge University Press.10.1017/CBO9781316287064CrossRefGoogle Scholar

Jibat, T., Hogeveen, H., Mourits, M. C. M. (2015). Review on dog rabies vaccination coverage in Africa: a question of dog accessibility or cost recovery? PLoS Negl Trop Dis, 9(2): e0003447. doi: 10.1371/journal.pntd.0003447.CrossRefGoogle ScholarPubMed

Lembo, T., Hampson, K., Haydon, D. T. et al. (2008). Exploring reservoir dynamics: a case study of rabies in the Serengeti ecosystem. J Appl Ecol, 45(4): 1246–1257. doi: 10.1111/j.1365-2664.2008.01468.x.CrossRefGoogle ScholarPubMed

Mallewa, M., Fooks, A. R., Banda, D. et al. (2007). Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerging Infectious Diseases, 13(1). doi: 10.3201/eid1301.060810.CrossRefGoogle ScholarPubMed

Mulipukwa, C. P., Mudenda, B., Mbewe, A. R. (2017). Insights and efforts to control rabies in Zambia: evaluation of determinants and barriers to dog vaccination in Nyimba district. PLoS Negl Trop Dis, 11(10): e0005946. doi.org/10.1371/journal.pntd.0005946.CrossRefGoogle ScholarPubMed

Octaria, R., Salyer, S. J., Blanton, J. et al. (2018). From recognition to action: a strategic approach to foster sustainable collaborations for rabies elimination. PLoS Negl Trop Dis, 12(10): e0006756. doi.org/10.1371/journal.pntd.0006756.CrossRefGoogle Scholar

Shim, E., Hampson, K., Cleaveland, S. et al. (2009). Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania. Vaccine, 27(51), 7167–7172. doi.org/10.1016/j.vaccine.2009.09.027.CrossRefGoogle ScholarPubMed

Swanepoel, R., Barnard, B. J., Meredith, C. D. et al. (1993). Rabies in southern Africa. J Vet Res, 60(4): 325–346. PMID: 7777317.Google ScholarPubMed

Théordoidès, J. (1986). Histoire de la Rage. Cave canem. Paris: Masson.Google Scholar

WHO. www.who.int/health-topics/rabies#tab=tab_1Google Scholar

WHO. www.who.int/news-room/fact-sheets/detail/rabiesGoogle Scholar

Yizengawet, E., Tamyalew, G., Mulu, W. et al. (2018). Incidence of human rabies virus exposure in northwestern Amhara, Ethiopia. BMC Infectious Diseases, 18: 597. doi.org/10.1186/s12879-018-3500-3.CrossRefGoogle Scholar

Aston, SJ, Ho, A, Jary, H et al. Etiology and risk factors for mortality in an adult community-acquired pneumonia cohort in Malawi. Am J Resp Crit Care Med. 2019;200:359–69.Google Scholar

Barr IG, Subbarao K. Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses. Nature. 2024;9:219.Google Scholar

Bonacina F, Boelle P-Y, Colizza V et al. Global patterns and drivers of influenza decline during the COVID-19 pandemic. Int J Infect Dis. 2023;128:132–9.10.1016/j.ijid.2022.12.042CrossRefGoogle Scholar

Centers for Disease Control and Prevention. Different Types of Flu Vaccines. CDC. 2019. www.cdc.gov/flu/prevent/different-flu-vaccines.htm.Google Scholar

Cohen, C, Simonsen, L, Kang, JW et al. Elevated influenza-related excess mortality in South African elderly individuals, 1998–2005. Clin Infect Dis. 2010;51(12):1362–9.10.1086/657314CrossRefGoogle ScholarPubMed

Cohen, C, Moyes, J, Tempia, S et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009–2011. Emerg Infect Dis. 2013;19(11):1766–74.10.3201/eid1911.130546CrossRefGoogle ScholarPubMed

Cohen, C, Walaza, S, Moyes, J et al. Epidemiology of severe acute respiratory illness (SARI) among adults and children aged ≥5 years in a high HIV-prevalence setting, 2009–2012. PLoS ONE 2015a;10(2):2009–12.Google Scholar

Cohen, C, Moyes, J, Tempia, S, Groome, M et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009–2013. PLoS ONE 2015b;10(3):e0118884.10.1371/journal.pone.0118884CrossRefGoogle ScholarPubMed

Cohen, C, Walaza, S, Treurnicht, FK et al. In and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa, 2009–2013. Clin Infect Dis. 2018;66(1):95–103.10.1093/cid/cix740CrossRefGoogle ScholarPubMed

Cohen, C, Tshangela, A, Valley-Omar, Z et al. Household transmission of seasonal influenza from HIV-infected and HIV-uninfected individuals in South Africa, 2013–2014. J Infect Dis. 2019;219(10):1605–15.10.1093/infdis/jiy702CrossRefGoogle ScholarPubMed

Cohen, C, Kleynhans, J, Moyes, J et al. Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study. 2021;18:863–74.Google Scholar

Dawa, JA, Chaves, SS, Nyawanda, B et al. National burden of hospitalized and non-hospitalized influenza-associated severe acute respiratory illness in Kenya, 2012–2014. Influenza Other Respi Viruses. 2018;12(1):30–7.10.1111/irv.12488CrossRefGoogle ScholarPubMed

Dia, N, Richard, V, Kiori, D et al. Respiratory viruses associated with patients older than 50 years presenting with ILI in Senegal, 2009 to 2011. BMC Infect Dis. 2014;14(1):2–7.10.1186/1471-2334-14-189CrossRefGoogle ScholarPubMed

Duque, J, McMorrow, ML, Cohen, AL. Influenza vaccines and influenza antiviral drugs in Africa: are they available and do guidelines for their use exist? BMC Public Health 2014;14(1):1–5.10.1186/1471-2458-14-41CrossRefGoogle Scholar

Ebell, MH, White, LL, Casault, T. A systematic review of the history and physical examination to diagnose influenza. J Am Board Fam Pract. 2004;17(1):1–5.10.3122/jabfm.17.1.1CrossRefGoogle ScholarPubMed

Green, A. Progress in influenza surveillance in Africa. Lancet 2018;391(10128):1345–6. http://dx.doi.org/10.1016/S0140-6736(18)30713-X.CrossRefGoogle ScholarPubMed

Hirve, S, Newman, LP, Paget, J, Azziz-Baumgartner, E. Influenza seasonality in the tropics and subtropics – when to vaccinate? PLoS ONE 2016. doi.org/10.1371/journal.pone.0153003.CrossRefGoogle Scholar

Ho, A, Aston, SJ, Jary, H et al. Impact of human immunodeficiency virus on the burden and severity of influenza illness in Malawian adults: a prospective cohort and parallel case-control study. Clin Infect Dis. 2018;66(6):865–76.10.1093/cid/cix903CrossRefGoogle ScholarPubMed

Iuliano, AD, Roguski, KM, Chang, HH et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018;391(10127):1285–300.10.1016/S0140-6736(17)33293-2CrossRefGoogle ScholarPubMed

Kim, H, Webster, RG, Webby, RJ. Influenza virus: dealing with a drifting and shifting pathogen. Viral Immunol. 2018;31(2):174–83.10.1089/vim.2017.0141CrossRefGoogle ScholarPubMed

Klein, EY, Monteforte, B, Gupta, A et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Resp Viruses 2016;10(5):394–403.10.1111/irv.12398CrossRefGoogle ScholarPubMed

Koegelenberg, CFN, Irusen, EM, Cooper, R et al. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. QJM. 2010;103(5):319–25.10.1093/qjmed/hcq022CrossRefGoogle ScholarPubMed

Lamb, YN. Cell-based quadrivalent inactivated influenza virus vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): a review in the prevention of influenza. Drugs 2019;79(12):1337–48. doi.org/10.1007/s40265-019-01176-z.Google ScholarPubMed

Long, JS, Mistry, B, Haslam, SM, Barclay, WS. Host and viral determinants of influenza A virus species specificity. Nat Rev Microbiol. 2019;17(2):67–81. doi.org/10.1038/s41579-018-0115-z.CrossRefGoogle ScholarPubMed

Maartens, G, Griesel, R, Dube, F, Nicol, M, Mendelson, M. Etiology of pulmonary infections in human immunodeficiency virus – infected inpatients using sputum multiplex real-time polymerase chain reaction. Clin Infect Dis. 2019. doi: 10.1093/cid/ciz332.CrossRefGoogle Scholar

Merckx, J, Wali, R, Schiller, I et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction. Ann Intern Med. 2017;167(6):395–409.10.7326/M17-0848CrossRefGoogle ScholarPubMed

Ope, MO, Katz, MA, Aura, B et al. Risk factors for hospitalized seasonal influenza in rural Western Kenya. PLoS ONE 2011. doi.org/10.1371/journal.pone.0020111.CrossRefGoogle Scholar

Petrova, VN, Russell, CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018;16(1):47–60. doi.org/10.1038/nrmicro.2017.118.CrossRefGoogle ScholarPubMed

Radin, JM, Katz, MA, Tempia, S et al. Influenza surveillance in 15 countries in Africa, 2006–2010. J Infect Dis. 2012;206(Suppl. 1):2006–10.Google ScholarPubMed

Rajaram, S, Boikos, C, Gelone, DK. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020. doi: 10.1177/2515135520908121.CrossRefGoogle Scholar

Richard, M, Fouchier, RAM. Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential. FEMS Microbiol Rev. 2015;40(1):68–85.10.1093/femsre/fuv039CrossRefGoogle ScholarPubMed

Schoen, K, Horvat, N, Guerreiro, NFC, De Castro, I, De Giassi, KS. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis. 2019;19(1). doi.org/10.1186/s12879-019-4592-0.CrossRefGoogle ScholarPubMed

Scott, JAG, Hall, AJ, Muyodi, C et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000;355:1225–30. doi: 10.1016/s0140-6736(00)02089-4.Google ScholarPubMed

Sellers, SA, Hagan, RS, Hayden, FG, Fischer, WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Resp Viruses 2017;11(5):372–93.10.1111/irv.12470CrossRefGoogle ScholarPubMed

Steffen, C, Diop, OM, Gessner, BD et al. Afriflu – International conference on influenza disease burden in Africa, 1–2 June 2010, Marrakech, Morocco. Vaccine 2011;29(3):363–9.10.1016/j.vaccine.2010.11.029CrossRefGoogle ScholarPubMed

Talbot, HK. Influenza in older adults. Infect Dis Clin North Am. 2017;31(4):757–66. doi.org/10.1016/j.idc.2017.07.005.CrossRefGoogle ScholarPubMed

Tan, J, Asthagiri Arunkumar, G, Krammer, F. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? Curr Opin Immunol. 2018; 53:45–50.10.1016/j.coi.2018.04.002CrossRefGoogle ScholarPubMed

Tang, S, Zhu, W, Wang, BZ. Influenza vaccines toward universality through nanoplatforms and given by microneedle patches. Viruses 2020. doi: 10.3390/v12111212.CrossRefGoogle Scholar

Tempia, S, Walaza, S, Moyes, J et al. Risk factors for influenza-associated severe acute respiratory illness hospitalization in South Africa, 2012–2015. Open Forum Infect Dis. 2017;4(1):2012–15.10.1093/ofid/ofw262CrossRefGoogle ScholarPubMed

Tempia, S, Walaza, S, Viboud, C et al. Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children 5 years of age in a high HIV prevalence setting – South Africa, 1998–2009. Clin Infect Dis. 2014;58(9):1241–9.10.1093/cid/ciu095CrossRefGoogle Scholar

Troeger, CE, Blacker, BF, Khalil, IA et al. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69–89.10.1016/S2213-2600(18)30496-XCrossRefGoogle Scholar

Uyeki, TM, Bernstein, HH, Bradley, JS et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1–47. doi.org/10.1093/cid/ciy866.CrossRefGoogle Scholar

Walaza, S, Tempia, S, Dawood, H et al. The impact of influenza and tuberculosis interaction on mortality among individuals aged ≥15 years hospitalized with severe respiratory illness in South Africa, 2010–2016. Open Forum Infect Dis. 2019;6(3):2010–16.10.1093/ofid/ofz020CrossRefGoogle ScholarPubMed

WHO. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ. 1980;58(4):585–91.Google Scholar

WHO. Weekly epidemiological record: vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461–76. http://orton.catie.ac.cr/cgi-bin/wxis.exe/?IsisScript=KARDEX.xis&method=post&formato=2&cantidad=1&expresion=mfn=003687.Google Scholar

Yamayoshi, S, Kawaoka, Y. Current and future influenza vaccines. Nat Med. 2019;25(2):212–20. doi.org/10.1038/s41591-018-0340-z.CrossRefGoogle ScholarPubMed

Centers for Disease Control and Prevention (2013). Progress toward poliomyelitis eradication – Nigeria, January 2007. www.cdc.gov/mmwr/preview/mmwrhtml/mm5734a4.htm.Google Scholar

Galasi, FM (2017). Poliomyelitis in Ancient Egypt? Neurological Sciences 38, 375.Google Scholar

Gonzalez, AR et al. (2017). Implementing the synchronized global switch from trivalent to bivalent oral polio vaccines—lessons learned from the global perspective. Journal of Infectious Diseases 216, S183–S192.10.1093/infdis/jiw626CrossRefGoogle Scholar

Gumede, N et al. (2014). Phylogeny of imported and reestablished wild polioviruses in the Democratic Republic of the Congo from 2006 to 2011. Journal of Infectious Diseases 210, S361–S367.10.1093/infdis/jiu375CrossRefGoogle ScholarPubMed

Gumede, N et al. (2018). Progress on the implementation of environmental surveillance in the African Region, 2011–2016. Journal of Immunological Sciences. www.immunologyresearchjournal.com/articles/progress-on-the-implementation-of-environmental-surveillance-in-the-african-region-20112016.html.10.29245/2578-3009/2018/si.1103CrossRefGoogle Scholar

Hamisu, AW et al. (2022). Characterizing environmental surveillance sites in Nigeria and their sensitivity to detect poliovirus and other enteroviruses. Journal of Infectious Diseases 225, 1377–1386. doi.org/10.1093/infdis/jiaa175.CrossRefGoogle ScholarPubMed

Hovi, T et al. (2012). Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiology & Infection 140, 1–13.10.1017/S095026881000316XCrossRefGoogle ScholarPubMed

DA, Kalkowska et al. (2021). Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Analysis 41, 329–348. doi: 10.1111/risa.13622.Google Scholar

Kohler, KA et al. (2002). Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bulletin of the World Health Organization 80, 210–216.Google ScholarPubMed

Macklin, GR et al. (2020). Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine. https://researchonline.lshtm.ac.uk/id/eprint/4656527/1/combined%20v5.pdf.Google Scholar

UNICEF (2021). Global overview of polio status. www.unicef.org/executiveboard/media/5501/file/2021_AS-SFS-Polio_Global_Overview-Information_note-EN-2021.05.20.pdf.Google Scholar

Wassilak, S et al. (2011). Outbreak of Type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. Journal of Infectious Diseases 203, 898–909.10.1093/infdis/jiq140CrossRefGoogle Scholar

WHO (2015). Report of the SAGE Polio Working Group Meeting 7–8 September 2015. www.who.int/immunization/sage/meetings/2015/october/2_SAGE_WG_report_draft_Final_clean.pdf?ua=1.Google Scholar

WHO (2019). www.who.int/news-room/fact-sheets/detail/poliomyelitis.Google Scholar

WHO (2020a). Africa kicks out wild polio. www.africakicksoutwildpolio.com/.Google Scholar

WHO (2020b). Novel oral polio vaccine (nOPV2). https://polioeradication.org/nopv2/.Google Scholar

WHO (2020c). Containment. https://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/.Google Scholar

WHO AFRO (2018). Business case for WHO immunization activities on the African continent, 2018–2030. Brazzaville: World Health Organization.Google Scholar

WHO PAHO (2020). www.paho.org/sites/default/files/faqs_ipv2_eng_10_june_2020.pdf.Google Scholar

Wolff, C et al. (2014). Progress toward laboratory containment of poliovirus after polio eradication. Journal of Infectious Diseases 210, S454–S458.10.1093/infdis/jit821CrossRefGoogle ScholarPubMed

Arvin, A (1996). Varciella-zoster virus. Clin Microbiol Rev; 9: 361–381.10.1128/CMR.9.3.361CrossRefGoogle Scholar

Bertran M, Andrews N, Davison C, et al (2023). Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis; 7: 828–83510.1016/S1473-3099(23)00057-9CrossRefGoogle Scholar

Centers for Disease Control and Prevention (2019). Monkeypox and Smallpox Vaccine Guidance. www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html.Google Scholar

Cevic M, Tomori O, Mbala P, et al. (2024). The 2023–2024 multi-source mpox outbreaks of Clade I MPXV in sub-Saharan Africa: Alarm bell for Africa and the World. IJID Reg, 12: 100397.Google Scholar

Colebunders, R, Mann, JM, Francis, H et al. (1988). Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis; 157: 314–318.10.1093/infdis/157.2.314CrossRefGoogle ScholarPubMed

Di Giulio, DB, Eckburg, PB (2004). Human monkeypox: an emerging zoonosis. Lancet Infect Dis; 4(1): 15–25.10.1016/S1473-3099(03)00856-9CrossRefGoogle ScholarPubMed

Fine, PE, Jezek, Z, Grab, B, Dixon, H (1988). The transmission potential of monkeypox virus in human populations. Int J Epidemiol; 17(3): 643–650.10.1093/ije/17.3.643CrossRefGoogle ScholarPubMed

Hussey, H, Abdullahi, L, Collins, J, Muloiwa, R, Hussey, G, Kagina, B (2017). Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review. BMC Infect Dis; 17(1): 717.10.1186/s12879-017-2815-9CrossRefGoogle ScholarPubMed

Jezek, Z, Szczeniowski, M, Paluku, KM, Mutombo, M (1987). Human monkeypox: clinical features of 282 patients. J Infect Dis; 156: 293–298.10.1093/infdis/156.2.293CrossRefGoogle ScholarPubMed

Kisalu, NK, Mokoli, JL (2017). Toward understanding the outcomes of monkeypox infection in human pregnancy. J Infect Dis; 216(7): 795–797.10.1093/infdis/jix342CrossRefGoogle ScholarPubMed

Ogoina, D, Iroezindu, M, James, HI et al (2020). Clinical course and outcome of human monkeypox in Nigeria. Clin Infect Dis; 71(8): 210–214.10.1093/cid/ciaa143CrossRefGoogle ScholarPubMed

Rimoin, AW, Mulembakani, PM, Johnston, SC et al. (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA; 107(37): 16262–16267.10.1073/pnas.1005769107CrossRefGoogle Scholar

Thornhill, JP, Barkati, S, Walmsley, S et al. Monkeypox virus infection in humans across 16 countries – April–June 2022. N Engl J Med 2022; 387(8): 679–691.10.1056/NEJMoa2207323CrossRefGoogle ScholarPubMed

Varela, FH, Pinto, LA, Scotia, SC (2019). Global impact of varicella vaccination programs. Hum Vaccin Immunother; 15(3): 645–657.10.1080/21645515.2018.1546525CrossRefGoogle ScholarPubMed

Yinka-Ogunleye, A, Aruna, O, Dahlat, M et al. (2019). Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis; 19(8): 872–879.10.1016/S1473-3099(19)30294-4CrossRefGoogle ScholarPubMed

Best, J.M. 2007. Rubella. Seminars in Fetal and Neonatal Medicine, Congenital and Opportunistic Infections 12, 182–192. doi.org/10.1016/j.siny.2007.01.017.CrossRefGoogle ScholarPubMed

Best, J.M., Enders, G. 2006. Laboratory diagnosis of rubella and congenital rubella. In Banatvala, J., Peckham, C. (eds) Perspectives in Medical Virology, Rubella Viruses, 39–77. Elsevier. doi.org/10.1016/S0168-7069(06)15003-X.CrossRefGoogle Scholar

da Silva e Sá, G.R., Camacho, L.A.B., Siqueira, M.M., Stavola, M.S., Ferreira, D.A. 2006. Seroepidemiological profile of pregnant women after inadvertent rubella vaccination in the state of Rio de Janeiro, Brazil, 2001–2002. Rev Panam Salud Publica 19, 371–378. doi.org/10.1590/s1020-49892006000600002.Google Scholar

Patel, M.K., Antoni, S., Danovaro-Holliday, M.C. et al. 2020. The epidemiology of rubella, 2007–18: an ecological analysis of surveillance data. Lancet Global Health 8, e1399–e1407. doi.org/10.1016/S2214-109X(20)30320-X.CrossRefGoogle ScholarPubMed

Vynnycky, E., Adams, E.J., Cutts, F.T. et al. 2016. Using seroprevalence and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996–2010: a systematic review. PLoS ONE 11, e0149160. doi.org/10.1371/journal.pone.0149160.CrossRefGoogle ScholarPubMed

WHO Regional Office for Africa. 2015. Regional strategic plan for immunization 2014–2020. www.afro.who.int/publications/regional-strategic-plan-immunization-2014-2020-0.Google Scholar

Azimi, P.H., Cramblett, H.G., Haynes, R.E. 1969. Mumps meningoencephalitis in children. JAMA 207, 509–512. doi.org/10.1001/jama.1969.03150160021004.CrossRefGoogle ScholarPubMed

Galazka, A.M., Robertson, S.E., Kraigher, A. 1999. Mumps and mumps vaccine: a global review. Bull World Health Organ 77, 3–14.Google ScholarPubMed

Hilleman, M.R., Buynak, E.B., Weibel, R.E., Stokes, J. 1968. Live, attenuated mumps-virus vaccine. New Engl J Med 278, 227–232. doi.org/10.1056/NEJM196802012780501.CrossRefGoogle ScholarPubMed

Hviid, A., Rubin, S., Mühlemann, K. 2008. Mumps. Lancet 371, 932–944. doi.org/10.1016/S0140-6736(08)60419-5.CrossRefGoogle ScholarPubMed

Ong, G., Goh, K.T., Ma, S., Chew, S.K. 2005. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 51, 294–298. doi.org/10.1016/j.jinf.2004.10.001.CrossRefGoogle Scholar

Vuori, M., Lahikainen, E.A., Peltonen, T. 1962. Perceptive deafness in connection with mumps. A study of 298 servicemen suffering from mumps. Acta Otolaryngol 55, 231–236. doi.org/10.3109/00016486209127357.CrossRefGoogle Scholar

WHO 2020. WHO immunization country profile. https://apps.who.int/immunization_monitoring/globalsummary.Google Scholar

Docherty, AB, Harrison, EM, Green, CA et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.10.1136/bmj.m1985CrossRefGoogle ScholarPubMed

Eyre, DW, Taylor, D, Purver, M et al. Effect of COVID-19 vaccination on transmission of alpha and delta variants. N Engl J Med 2022. doi: 10.1056/NEJMoa2116597.CrossRefGoogle Scholar

Knight, SR, Ho, A, Pius, R et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020; 370. doi: 10.1136/bmj.m3339.Google ScholarPubMed

The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med 2020. doi: 10.1056/NEJMoa2021436.CrossRefGoogle Scholar

Therapeutics and COVID-19: living guideline. www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2022.1.Google Scholar

Zhu, N, Zhang, D, Wang, W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020. doi: 10.1056/NEJMoa2001017.CrossRefGoogle Scholar